Table 1.
Characteristics of patients in the cohort grouped by patients included in the analyses versus patients not included in the analyses
| Asthmaa | COPDa | |||||
|---|---|---|---|---|---|---|
| Total cohort (n = 35,384) | In analyses (n = 9,308) | Not in analysesb (n = 26,076) | Total cohort (n = 19,057) | In analyses (n = 4,825) | Not in analysesb (n = 14,232) | |
| Male, n (%) | 14,619 (41.3) | 3597 (38.6) | 11,022 (42.3) | 10,072 (52.9) | 2405 (49.8) | 7667 (53.9) |
| Asthma, n (%) | 3286 (17.2) | 801c (16.6) | 2485c (17.5) | |||
| COPD, n (%) | 3286 (9.3) | 801 (8.6) | 2485 (9.5) | |||
| ICS, n (%) | 20,737 (58.6) | 9308 (100.0) | 11,429 (43.8) | 10,674 (56.0) | 4825 (100.0) | 5849 (41.1) |
| LABA single inhaler, n (%) | 4533 (14.2) | 1631 (17.5) | 2902 (12.8) | 4547 (28.2) | 1418 (29.4) | 3129 (27.7) |
| LAMA single inhaler, n (%) | 5552 (17.4) | 1842 (19.8) | 3710 (16.4) | 11,952 (74.2) | 3573 (74.1) | 8379c (74.2) |
| LAMA/LABA combined inhaler, n (%) | 582 (1.8) | 162 (1.7) | 420c (1.9) | 1298 (8.1) | 414 (8.6) | 884c (7.8) |
COPD chronic obstructive pulmonary disease
aAll patients with a diagnosis including asthma–COPD overlap
bMissing values on use of LABA and/or LAMA of asthma (n = 3393) and COPD (n = 2939) compared between the two subgroups were statistically significant (p < 0.05)
cNo statistical significant difference (p > 0.05). All other differences in patient characteristics are significant